Evidence map›Paper›PMID 37201119›Full record

ArticleFrontiers in cellular and infection microbiology2023

The value of biofilm testing to guide antimicrobial stewardship in chronic respiratory diseases.

Laia Fernández-Barat, Nil Vázquez Burgos, Victoria Alcaraz, Leticia Bueno-Freire, Ruben López-Aladid, Roberto Cabrera, Albert Gabarrús, Andrea Palomeque, Patricia Oscanoa, Adrian Ceccato and 8 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Early and matureBiofilm · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Laia Fernández-BaratCellex Laboratory, CibeRes (CB06/06/0028)-Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Barcelona, Spain.
Nil Vázquez BurgosCellex Laboratory, CibeRes (CB06/06/0028)-Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Barcelona, Spain.
Victoria AlcarazCellex Laboratory, CibeRes (CB06/06/0028)-Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Barcelona, Spain.
Leticia Bueno-FreireCellex Laboratory, CibeRes (CB06/06/0028)-Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Barcelona, Spain.
Ruben López-AladidCellex Laboratory, CibeRes (CB06/06/0028)-Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Barcelona, Spain.
Roberto CabreraCellex Laboratory, CibeRes (CB06/06/0028)-Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Barcelona, Spain.
Albert GabarrúsCellex Laboratory, CibeRes (CB06/06/0028)-Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Barcelona, Spain.
Andrea PalomequeCellex Laboratory, CibeRes (CB06/06/0028)-Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Barcelona, Spain.
Patricia OscanoaCellex Laboratory, CibeRes (CB06/06/0028)-Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Barcelona, Spain.
Adrian CeccatoCellex Laboratory, CibeRes (CB06/06/0028)-Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Barcelona, Spain.
Ana MotosCellex Laboratory, CibeRes (CB06/06/0028)-Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Barcelona, Spain.
Rosanel AmaroCellex Laboratory, CibeRes (CB06/06/0028)-Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Barcelona, Spain.
Thierry BernardiBioFilm Pharma SAS, Lyon, France.
Christian ProvotBioFilm Pharma SAS, Lyon, France.
Alba Soler-ComasCellex Laboratory, CibeRes (CB06/06/0028)-Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Barcelona, Spain.
Laura MuñozMicrobiology Service, Hospital Clinic, Barcelona, Spain.
Jordi VilaMicrobiology Service, Hospital Clinic, Barcelona, Spain.
Antoni TorresCellex Laboratory, CibeRes (CB06/06/0028)-Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Barcelona, Spain.
Hospital Clínic de Barcelona · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESUniversitat de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Biofilm production is an important yet currently overlooked aspect of diagnostic microbiology that has implications for antimicrobial stewardship. In this study, we aimed to validate and identify additional applications of the BioFilm Ring Test® (BRT) for Pseudomonas aeruginosa (PA) isolates from patients with bronchiectasis (BE). Materials and methods: Sputa were collected from BE patients who had at least one PA positive culture in the previous year. We processed the sputa to isolate both mucoid and non-mucoid PA, and determined their susceptibility pattern, mucA gene status, and presence of ciprofloxacin mutations in QRDR genes. The Biofilm production index (BPI) was obtained at 5 and 24 hours. Biofilms were imaged using Gram staining. Results: We collected 69 PA isolates, including 33 mucoid and 36 non-mucoid. A BPI value below 14.75 at 5 hours predicted the mucoid PA phenotype with 64% sensitivity and 72% specificity. Conclusion: Overall, our findings suggest that the fitness-cost associated with the mucoid phenotype or ciprofloxacin resistance is shown through a time-dependent BPI profile. The BRT has the potential to reveal biofilm features with clinical implications.

Indexed as

Antimicrobial StewardshipPseudomonas InfectionsRespiratory Tract DiseasesAnti-Bacterial AgentsBiofilmsCiprofloxacinHumansPhenotypePseudomonas aeruginosaAnti-Bacterial AgentsCiprofloxacinantimicrobial agentsantimicrobial resistancesbiofilmbiofilm diagnosePseudomonas aeruginosa

Identifiers

PMID37201119
PMCPMC10187140
OpenAlexW4367852919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.